Q-omics provides the consensus-scored FTLP10 profile across patient tissues and cancer cell-line models. FTLP10 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, FTLP10 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, FTLP10 RNA expression shows 6,006 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LUSC, HNSC, and UCEC as cancer lineages where FTLP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP10 survival associations across molecular data types. FTLP10 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP10 RNA expression–survival associations across cancer types. High FTLP10 expression shows unfavorable associations in UCS, CHOL and BLCA, but favorable associations in LUSC, MESO and HNSC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for FTLP10 RNA expression.
This table summarizes FTLP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP10 shows lower tumor expression in HNSC, KIRP and LIHC and higher tumor expression in LUSC and UCEC. The HNSC box plot shows higher FTLP10 RNA expression in normal versus tumor tissue (log2 FC = −1.316, t-test p < 0.001).
This table shows molecular features associated with FTLP10 in patient tissues and cancer cell lines. In patient samples, FTLP10 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
